Search results

1. Evaluation of primary and secondary molecular disorders determinig drug resistance from a group of proteasome inhibitors…

Principal investigator: prof. Tadeusz Jerzy Robak

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: OPUS 12, Panel: NZ5

2. Evaluation of the relationship between doxorubicin resistance, epithelial-mesenchymal plasticity, and effects of selecte…

Principal investigator: Dominika Kunachowicz

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Farmaceutyczny z Oddziałem Analiutyki Medycznej

Call: PRELUDIUM 23, Panel: NZ5

3. Targeted poloxamer micelles with selected drugs as a strategy for overcoming the mechanisms of multidrug resistance in p…

Principal investigator: prof. Tomasz Adam Gośliński

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: PRELUDIUM BIS 4, Panel: NZ7

4. In search for molecular targets to overcome doxorubicin resistance in triple-negative breast cancer with the use of inno…

Principal investigator: Anna Karolina Pogorzelska

Narodowy Instytut Leków

Call: PRELUDIUM 20, Panel: NZ7

5. Galactosylceramide as a regulator of apoptotic gene expression and modulator of drug resistance in breast cancer cells.

Principal investigator: prof. Maciej Ugorski

Uniwersytet Przyrodniczy we Wrocławiu, Wydział Medycyny Weterynaryjnej

Call: OPUS 18, Panel: NZ5

6. Endocytosis-stimulating antibodies against multidrug transporters as drug carriers

Principal investigator: dr hab. Łukasz Pułaski

Instytut Biologii Medycznej PAN

Call: OPUS 10, Panel: NZ7

7. Identification and targeting molecular drug resistance mechanisms in adult B-cell acute lymphoblastic leukemia

Principal investigator: dr hab. Przemysław Juszczyński

Instytut Hematologii i Transfuzjologii

Call: OPUS 1, Panel: NZ4

8. Impact of cytostatic drugs present in the environment on Gram-negative bacteria: mechanisms of adaptation and implicatio…

Principal investigator: Adam Grzywaczyk

Politechnika Poznańska

Call: PRELUDIUM 23, Panel: NZ9

9. Analysis of semaphorin 3 (SEMA3), protocadherin 9 (PCDH9) and S 100 calcium binding proteinA3 (S100A3) expression in pro…

Principal investigator: prof. Radosław Januchowski

Uniwersytet Zielonogórski, Collegium Medicum

Call: OPUS 21, Panel: NZ5

10. Zinc Deficiency: An essential Variable for the Induction od Resistance to Antidepressants

Principal investigator: dr Anna Maria Rafało-Ulińska

Instytut Farmakologii PAN

Call: PRELUDIUM 13, Panel: NZ5

11. The study of the contribution of telomerase regulation to cancer cells resistance to DNA-damaging drugs

Principal investigator: dr hab. Błażej Rubiś

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Farmaceutyczny

Call: OPUS 11, Panel: NZ7

12. Optogenetic and chemogenetic identification of brain circuits and cellular mechanisms underlying antidepressants resista…

Principal investigator: prof. Mariusz Papp

Instytut Farmakologii PAN

Call: OPUS 26, Panel: NZ7

13. Cuproptosis, a novel pathway of regulated cell death as a therapeutic target in treatment-naïve and targeted therapy-res…

Principal investigator: dr hab. Mariusz Łukasz Hartman

Uniwersytet Medyczny w Łodzi, Wydział Lekarski

Call: OPUS 25, Panel: NZ5

14. Bis(benzosiloxaboroles) as a new class of potential antibiotics - a perspective solution to growing problem of antimicro…

Principal investigator: Krzysztof Nowicki

Politechnika Warszawska, Wydział Chemiczny

Call: PRELUDIUM 22, Panel: ST5

15. Regulatory network and interactome of inner membrane drug/metabolite transporters in bacteria – implications for physiol…

Principal investigator: dr hab. Aneta Agnieszka Bartosik

Instytut Biochemii i Biofizyki PAN

Call: OPUS 23, Panel: NZ2

16. Electroporation-based manipulation of drug resistance in cancer using novel nanosecondasymmetrical pulse sequences

Principal investigator: dr hab. Julita Kulbacka

Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu, Wydział Farmaceutyczny z Oddziałem Analiutyki Medycznej, Wydział Farmaceutyczny

Call: DAINA 2, Panel: NZ7

17. CBR1-dependent metabolism and ABCB1-dependent effux of doxorubicin - search for a novel mechanism of reversing resistanc…

Principal investigator: Kamil Tomasz Piska

Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum; Wydział Farmaceutyczny

Call: PRELUDIUM 13, Panel: NZ7

18. Computational methods for identyfiing drug resistance associated mutations in bacterial strains

Principal investigator: Michał Jan Woźniak

Uniwersytet Warszawski

Call: PRELUDIUM 3, Panel: ST6

19. Role of autophagy in chemoresistance of glioblastoma stem-like cells

Principal investigator: dr Iwona Anna Ciechomska

Instytut Biologii Doświadczalnej im. M. Nenckiego PAN

Call: OPUS 2, Panel: NZ3

20. Role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to imatinib

Principal investigator: prof. Janusz Błasiak

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

Call: OPUS 2, Panel: NZ2

21. Evaluation of contamination of Vistula River near Warsaw by pharmaceuticaly active compounds and metabolites

Principal investigator: prof. Grzegorz Leszek Nałęcz-Jawecki

Warszawski Uniwersytet Medyczny, Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej

Call: OPUS 2, Panel: NZ7

22. New drug carriers in targeted anticancer therapy

Principal investigator: prof. Artur Piotr Terzyk

Uniwersytet Mikołaja Kopernika, Wydział Chemii

Call: OPUS 1, Panel: ST5

23. Functional nanomaterials based on drug–lipid–ligands as targeted delivery systems for anticancer agents in lung adenocar…

Principal investigator: Piotr Paweł Szyk

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: PRELUDIUM 24, Panel: NZ7

24. Could fibroblast senescence and their resistance to apoptosis be the hidden drivers behind endometrial fibrosis in equin…

Principal investigator: dr Katarzyna Karolina Piotrowska-Tomala

Instytut Rozrodu Zwierząt i Badań Żywności PAN

Call: OPUS 28, Panel: NZ5

25. Improving rational prescribing for UTI in frail elderly.

Principal investigator: prof. Maciej Godycki-Ćwirko

Uniwersytet Medyczny w Łodzi

Call: UNISONO, Panel: NZ7

26. Nanoencapsulated Photosensitizing Drugs for Photodynamic Therapy of Resistant Cancers and Microbes

Principal investigator: dr Janusz Marcin Dąbrowski

Uniwersytet Jagielloński, Wydział Chemii

Call: SONATA BIS 6, Panel: NZ7

27. Supramolecular nanoparticles able to block calcium channels in cancer cells

Principal investigator: dr hab. Marek Brzeziński

Centrum Badań Molekularnych i Makromolekularnych PAN

Call: SONATA BIS 14, Panel: ST11

28. New strategy for overcoming resistance to chemotherapy of ovarian cancer by modulation of the canonical and non-canonica…

Principal investigator: prof. Radosław Januchowski

Uniwersytet Zielonogórski, Collegium Medicum

Call: OPUS 22, Panel: NZ5

29. Gankyrin protein as a new potential therapeutic target in multiple myeloma

Principal investigator: dr hab. Irena Misiewicz-Krzemińska

Instytut Hematologii i Transfuzjologii

Call: OPUS 18, Panel: NZ5

30. Fighting antibiotic-resistant superbugs with anti-persister compounds targeting the strigent response

Principal investigator: dr hab. Ewa Laskowska

Uniwersytet Gdański

Call: UNISONO, Panel: NZ6

31. Exploring Antimicrobial Potential of Mytilus Genomic Resources

Principal investigator: prof. Artur Stanisław Burzyński

Instytut Oceanologii PAN

Call: OPUS 29, Panel: NZ8

32. Titanium Dioxide in a New Light: Reducing Toxicity and Improving the Photoprotective Properties of TiO2 Through Nanopart…

Principal investigator: Michał Jan Gackowski

Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Call: PRELUDIUM 24, Panel: NZ7

33. Therapeutic evaluation of anti-fibrotic agents for thyroid eye disease (TED) in a preclinical mouse model

Principal investigator: Paweł Franciszek Tyrna

CENTRUM MEDYCZNE KSZTAŁCENIA PODYPLOMOWEGO

Call: PRELUDIUM 24, Panel: NZ6

Projects search